Optimising the NHS – How will medicines be valued in integrated systems?

Pharma Market Access Insights - from Mtech Access

How will medicines be valued in the newly integrated world of the NHS? What are the risks and benefits of a single national formulary? What else is changing? And what does this mean for market access?

Ellen Rule (Programme Director of the Gloucestershire Integrated Care System [ICS] and Director of Transformation and Service Redesign, Gloucestershire Clinical Commissioning Group [CCG]) joins Tom Clarke (Director, Mtech Access) to explore all this and more.
Tom Clarke and Ellen Rule discuss the key points highlighted in her recent proposals ‘The systematisation of medicines optimisation: Why medicines optimisation is a priority for integrated care systems and how it can be improved’, including:

• The risks and benefits of a single national formulary and what this means for market access
• How to support system and local networks to implement pan-ICS approaches to medicines optimisation
• How industry can distinguish their product in this new world where systems become automated to substitute generics and biosimilars for branded medicines

Ellen and Tom discussed the implications of this paper, and the broader context of value in integrated care.
For more information visit https://mtechaccess.co.uk/optimising-nhs-medicines-valued-integrated-systems/
This podcast was originally recorded as a live webinar on 22nd October 2021.
Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

فصل ها

1. What does your role of ICS Programme Director mean and what does the system look like? (00:01:35)

2. How is the system developing and how are NHS structures changing? (00:05:55)

3. How are perspectives around value evolving? (00:15:05)

4. How will specialised commissioning be managed? (00:24:30)

5. Medicines optimisation and Ellen Rule's paper (00:27:30)

6. Can you expand on the suggestion of a single national formulary? (00:36:50)

7. Will systematisation have an impact on how guidelines are implemented? (00:39:20)

8. What happens if there's not a more systematic approach to medicines in the future? (00:44:45)

9. How best can Pharma and Life Sciences support the NHS with medicines optimisation? (00:48:55)